Current Issues in Molecular Biology (Feb 2022)

<i>ICOS</i> Gene Polymorphisms (IVS1 + 173 T/C and c. 1624 C/T) in Primary Sjögren’s Syndrome Patients: Analysis of ICOS Expression

  • José Antonio García-Espinoza,
  • José Francisco Muñoz-Valle,
  • Mariel García-Chagollán,
  • Jorge Hernández-Bello,
  • Claudia Azucena Palafox-Sánchez,
  • Erika Fabiola López-Villalobos,
  • Gabriela Athziri Sánchez-Zuno,
  • Gloria Esther Martínez-Bonilla,
  • Sergio Cerpa-Cruz,
  • Francisco Josue Carrillo-Ballesteros,
  • Edith Oregon-Romero

DOI
https://doi.org/10.3390/cimb44020053
Journal volume & issue
Vol. 44, no. 2
pp. 764 – 776

Abstract

Read online

Background: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, which affects exocrine glands. T cell activation is a trigger mechanism in the immune response. Hyperreactivity of T cells and antibody production are features in pSS. ICOS can be critical in the pathogenesis of pSS. Methods: A total of 134 pSS patients and 134 control subjects (CS) were included. Genotyping was performed by PCR-RFLP. ICOS mRNA expression was quantified by real-time PCR, and CD4+ ICOS+ T cells were determined by flow cytometry. Results: The ICOS IVS1 + 173 T>C polymorphisms were not associated with susceptibility to pSS (p = 0.393, CI = 0.503–1.311). However, the c.1624 C>T polymorphism was associated with a reduction in the risk of development of pSS (p = 0.015, CI = 0.294–0.884). An increase in ICOS mRNA expression in patients was observed (3.7-fold). Furthermore, pSS patients showed an increase in membranal-ICOS expression (mICOS). High expression of mICOS (MFI) was associated with lymphocytic infiltration. Conclusions: The IVS1 + 173 polymorphism is not a genetic marker for the development of pSS, while c.1624 T allele was associated with a low risk. However, elevated mICOS expression in pSS patients with high lymphocytic infiltration was found. ICOS may have an important role in the immunopathogenesis of pSS and should be analyzed in T cell subsets in pSS patients as a possible disease marker.

Keywords